Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline

No disease-modifying therapies are currently available for Alzheimer’s disease (AD) in Europe. Current evidence from clinical trials testing anti-beta amyloid (Aβ) monoclonal antibodies (mAbs) in patients with early AD, though, suggests a likely marketing authorization in the next years. Since the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Massimo, Cecchetti, Giordano, Cagnin, Annachiara, Marra, Camillo, Nobili, Flavio, Parnetti, Lucilla, Agosta, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188416/
https://www.ncbi.nlm.nih.gov/pubmed/36892630
http://dx.doi.org/10.1007/s00415-023-11642-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188416/
https://www.ncbi.nlm.nih.gov/pubmed/36892630
http://dx.doi.org/10.1007/s00415-023-11642-0

Ejemplares similares